Cyclosporine

Generic Name
Cyclosporine
Brand Names
Cequa, Gengraf, Neoral, Restasis, Sandimmune, Verkazia, Vevye, Ikervis
Drug Type
Small Molecule
Chemical Formula
C62H111N11O12
CAS Number
59865-13-3
Unique Ingredient Identifier
83HN0GTJ6D
Background

Cyclosporine is a calcineurin inhibitor known for its immunomodulatory properties that prevent organ transplant rejection and treat various inflammatory and autoimmune conditions. It is isolated from the fungus Beauveria nivea. Initially manufactured by Sandoz and approved for use by the FDA in 1983, cyclosporine is now available in various products by Novartis (previously known as Sandoz).

Indication

Cyclosporine is approved for a variety of conditions. Firstly, it is approved for the prophylaxis of organ rejection in allogeneic kidney, liver, and heart transplants. It is also used to prevent bone marrow transplant rejection. For the above indications, cyclosporine can be used in conjunction with azathioprine and corticosteroids. Finally, cyclosporine can be used in patients who have chronic transplant rejection and have received previous immunosuppressive therapy and to prevent or treat graft-versus-host disease (GVHD).

Secondly, cyclosporine is used for the treatment of patients with severe active rheumatoid arthritis (RA) when they no longer respond to methotrexate alone. It can be used for the treatment of adult non-immunocompromised patients with severe, recalcitrant, plaque psoriasis that have failed to respond to at least one systemic therapy or when systemic therapies are not tolerated or contraindicated. The ophthalmic solution of cyclosporine is indicated to increase tear production in patients suffering from keratoconjunctivitis sicca. In addition, cyclosporine is approved for the treatment of steroid dependent and steroid-resistant nephrotic syndrome due to glomerular diseases which may include minimal change nephropathy, focal and segmental glomerulosclerosis or membranous glomerulonephritis.

A cyclosporine ophthalmic emulsion is indicated in the treatment of vernal keratoconjunctivitis in adults and children.

Off-label, cyclosporine is commonly used for the treatment of various autoimmune and inflammatory conditions such as atopic dermatitis, blistering disorders, ulcerative colitis, juvenile rheumatoid arthritis, uveitis, connective tissue diseases, as well as idiopathic thrombocytopenic purpura.

Associated Conditions
Atopic Dermatitis, Bone Marrow Transplant Rejection, Chronic transplant rejection, Connective Tissue Disorders, Dry Eyes, Graft-versus-host Disease (GVHD), Heart Transplant Rejection, Immune Thrombocytopenia (ITP), Interstitial Cystitis, Juvenile Idiopathic Arthritis (JIA), Kidney Transplant Rejection, Liver Transplant Rejection, Lupus Nephritis, Nephrotic Syndrome, Ocular Rosacea, Rheumatoid Arthritis, Severe Ulcerative Colitis, Steroid Dependent Nephrotic Syndrome, Steroid Resistant Nephrotic Syndrome, Uveitis, Vernal Keratoconjunctivitis, Blistering disorder, Refractory Ulcerative colitis, Severe Psoriasis, Severe, active Rheumatoid arthritis, Severe, recalcitrant Plaque psoriasis, Suppressed tear production
Associated Therapies
-

Thymoglobulin and Cyclosporine in Patients With Aplastic Anemia or Myelodysplastic Syndrome

First Posted Date
2008-12-11
Last Posted Date
2013-03-12
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
53
Registration Number
NCT00806598
Locations
🇺🇸

UT MD Anderson Cancer Center, Houston, Texas, United States

Hematopoietic Cell Transplantation for Pediatric Patients With Hematologic Malignancies

First Posted Date
2008-11-21
Last Posted Date
2013-07-30
Lead Sponsor
University of Utah
Target Recruit Count
47
Registration Number
NCT00795132
Locations
🇺🇸

Primary Children's Medical Center, Salt Lake City, Utah, United States

A Prospective, Randomized, Placebo and Active Comparator Controlled Study of CP-690,550 in Subjects With Dry Eye.

First Posted Date
2008-11-04
Last Posted Date
2013-04-09
Lead Sponsor
Pfizer
Target Recruit Count
327
Registration Number
NCT00784719
Locations
🇺🇸

Pfizer Investigational Site, San Antonio, Texas, United States

Aerosol Cyclosporine in Chronic Obstructive Pulmonary Disease (COPD)

First Posted Date
2008-10-31
Last Posted Date
2012-12-11
Lead Sponsor
University of Pittsburgh
Target Recruit Count
8
Registration Number
NCT00783107
Locations
🇺🇸

University of Pittsburgh, Pittsburgh, Pennsylvania, United States

Randomized Trial of Cyclosporine and Tacrolimus Therapy With Steroid Withdrawal in Living-Donor Renal Transplantation

Not Applicable
Completed
Conditions
Interventions
First Posted Date
2008-10-22
Last Posted Date
2011-04-22
Lead Sponsor
Samsung Medical Center
Target Recruit Count
131
Registration Number
NCT00777933
Locations
🇰🇷

Transplantation Center, Samsung Medical Center, Seoul, Korea, Republic of

Ciclosporin in HTLV-1 Associated Myelopathy/ Tropical Spastic Paraparesis (HAM/TSP)

Phase 2
Completed
Conditions
Interventions
First Posted Date
2008-10-16
Last Posted Date
2021-09-09
Lead Sponsor
Imperial College London
Target Recruit Count
7
Registration Number
NCT00773292
Locations
🇬🇧

National Centre for Human Retrovirology, London, United Kingdom

Diabetogenicity of Cyclosporine and Tacrolimus

First Posted Date
2008-10-06
Last Posted Date
2011-11-08
Lead Sponsor
University of Aarhus
Target Recruit Count
18
Registration Number
NCT00766909
Locations
🇩🇰

Department of Nephrology, Aarhus University Hospital, Skejby, Aarhus, Jutland, Denmark

© Copyright 2024. All Rights Reserved by MedPath